Powered by
ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ:ESPR) has provided a development update for its lead drug candidate, bempedoic acid, and financial results for the first quarter ended March 31. “The potential of …
ANN ARBOR – Esperion Therapeutics Inc. (NASDAQ:ESPR), the pharmaceutical startup developing a new cholesterol-fighting drug, reported a loss of $60 million in the fourth quarter, up from a loss of $37.9 …
ANN ARBOR — Esperion Therapeutics Inc. (Nasdaq: ESPR), the Ann Arbor company developing new treatments for high cholesterol, announced positive rsults from a Phase 2 clinical study of its drug …
ANN ARBOR — Esperion Therapeutics Inc. (Nasdaq:ESPR), Monday announced the start of a Phase 3 study to assess the safety and efficacy of a combination pill containing its cholesterol-fighter, bempedoic …
ANN ARBOR — Esperion Therapeutics Inc. (NASDAQ:ESPR), the Ann Arbor-based pharmaceutical startup, announced the initiation of a Phase 2 clinical study (1002-039) to assess the efficacy and safety of its …
ANN ARBOR — Esperion Therapeutics Inc. (NASDAQ:ESPR), the pharmaceutical startup working on a new class of cholesterol-reducing drugs, provided a drug development update and financial results for 2016.